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t   3Cerebral edema remains a significant cause of morbidity and mortality in patients with acute 
liver failure (ALF) and has been linked to elevated blood ammonia levels. L-ornithine 
phenylacetate (OPA) may decrease ammonia by promoting its renal excretion as 
phenylacetylglutamine (PAGN), decreasing the risk of cerebral edema. We evaluated the safety, 
tolerability, and pharmacokinetics of OPA in patients with ALF and acute liver injury (ALI), 
including those with renal failure. Forty-seven patients with ALI/ALF and ammonia ≥60µM 
were enrolled. Patients received OPA in a dose escalation scheme from 3.3g/24h to 10g/24h; 15 
patients received 20g/24h throughout the infusion for up to 120h. Plasma phenylacetate 
concentrations [PA] were uniformly below-target (<75µg/ml) in those receiving 3.3g/24h 
(median[IQR] 5.0[5.0]µg/ml), and increased to target levels in all but one who received 20g/24h 
(150[100]µg/ml). Plasma [PAGN] increased, and conversion of PA to PAGN became saturated, 
with increasing OPA dose. Urinary PAGN clearance and creatinine clearance were linearly 
related (r=0.831, P<0.0001). Mean ammonia concentrations based on the area-under-the-curve 
decreased to a greater extent in patients who received 20g/24h OPA compared to those who 
received the 3.3 or 6.7g/24h maximal dose (P=0.046 and 0.022, respectively). Of the reported 
serious adverse events (AEs) including 11 deaths, none were attributable to study medication. 
The only non-serious AEs possibly related to study drug were headache and nausea/vomiting. 
Conclusions. OPA was well-tolerated in patients with ALI/ALF, and no safety signals were 
identified. Target [PA] was achieved at infusion rates of 20g/24h, leading to ammonia excretion 
in urine as PAGN in proportion to renal function. Randomized, controlled studies of high-dose 
OPA are needed to determine its utility as an ammonia-scavenging agent in patients with ALF.   
Page 3 of 38
Hepatology
Hepatology









t   4 The syndrome of acute liver failure (ALF) evolves rapidly from primary liver injury to 
secondary multi-organ system failure (MOSF), and results in death or the need for liver 
transplantation (LT) in more than half of affected patients(1). The risk of developing cerebral 
edema, a systemic complication of ALF which dramatically increases the incidence of poor 
outcome(2), is directly proportional to blood ammonia concentrations(3). 
In healthy patients, ammonia produced in the gut is bio-transformed into urea and 
eliminated in urine. In patients with ALF, however, ammonia accumulates in the blood due to 
deficient activity of hepatic urea cycle enzymes. In the brain, ammonia is taken up by astrocytes 
and detoxified by glutamine synthetase into glutamine (GLN), an osmotically-active 
molecule(4). The rapid accumulation of GLN in the brain of patients with ALF is believed to 
overwhelm compensatory mechanisms which shed intracellular osmolytes, creating an osmotic 
gradient that results in astrocyte swelling, an increase in brain volume, and intracranial 
hypertension. Sustained astrocyte swelling can become unresponsive to medical therapy with 
osmotic agents such as mannitol or hypertonic saline, resulting in uncal herniation and death. 
Therefore, a strong rationale exists for ammonia-lowering therapies to treat hyperammonemia 
and prevent cerebral edema in patients with ALF.  
 Effective ammonia-lowering agents have been developed for infants and children with 
inborn errors of urea cycle enzymes(5). Ammonia-lowering agents have received comparatively 
little study in adults with acute or chronic liver disease. L-ornithine L-aspartate (LOLA) is a 
compound hypothesized to lower ammonia by providing a precursor for glutamate synthesis 
(ornithine [ORN]), which serves to bind ammonia to form GLN. Unfortunately, a large, 
randomized, placebo-controlled study of LOLA in adults with ALF (6) failed to lower blood 
ammonia levels or improve survival. Jalan and Lee have hypothesized the lack of efficacy of 
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t   5LOLA in ALF may be due to the deamidation of GLN by glutaminases in the gut and other 
tissues, thereby liberating ammonia back into the circulation(7).  
 Other ammonia-lowering agents have been developed to prevent the deamidation of 
GLN. Phenylacetate (PA) promotes renal excretion of glutamine and has been used for this 
purpose in children with urea cycle defects(8). L-ornithine phenylacetate (OPA), a salt which 
provides both a substrate for the synthesis of glutamine, ORN, as well as a GLN-scavenging 
agent, PA, is hypothesized to promote the renal excretion of phenylacetylglutamine (PAGN) 
(Supplemental Figure 1)(9). Studies in rat (10) and pig (11) models of ALF have documented a 
reduction of blood ammonia during OPA infusion and proved the ability of this compound to act 
as an effective ammonia scavenger. However, the safety of this compound in humans remains 
somewhat uncertain considering that astrocyte mitochondria in experimental animals express 
glutaminases, which have the potential to deamidate GLN and release ammonia, theoretically 
increasing neurotoxicity(12). 
 Previous studies have suggested that OPA is, in fact, safe and well-tolerated in patients 
with cirrhosis, and have demonstrated its ability to promote nitrogen excretion in urine as PAGN 
(13, 14). The present exploratory study is the first to test the safety and tolerability of escalating 
doses of OPA in humans with acute liver injury (ALI; no encephalopathy) and ALF, who often 
have dramatically higher serum ammonia levels than do patients with cirrhosis. Secondary 
objectives included the evaluation of the pharmacokinetic (PK) and pharmacodynamics of OPA 
in hyperammonemic patients with ALI/ALF.   
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t   6Patients and Methods. 
 Since its founding in 1998, more than 3,000 adult patients have been enrolled in the ALF 
Study Group Registry wherein detailed data and daily bio-samples are collected over 7 days. All 
study patients met criteria for ALF or ALI for the Registry, as defined previously(1, 15). 
Consent was provided by the patient if there were no evident hepatic encephalopathy (ALI), and 
the patients’ legal next of kin, if the patient exhibited signs of encephalopathy (ALF). Separate 
consents were obtained for the Registry and the OPA clinical trial. The study was approved by 
each institution’s Internal Review Board, conforming to the ethical guidelines of the 1975 
Declaration of Helsinki.  
 The primary objective of the study was to evaluate the safety and tolerability of 
ascending doses of OPA in patients with ALF and severe ALI with and without renal 
impairment. Secondary objectives included the evaluation of the PK and pharmacodynamic 
profile of OPA in patients with ALI/ALF. Exploratory objectives included the evaluation of the 
effects of OPA on serum ammonia.  
 Study Population. The study was conducted at 8 US liver transplant centers which have 
demonstrated high-volume enrollment in the ALF Study Group Registry. A total of 301 patients 
were screened to achieve enrollment of 47 patients meeting all criteria (Supplemental Figure 2). 
Inclusion criteria included age 18-65 years, with ALI or ALF as defined, and a plasma ammonia 
of ≥60µM within 8 hours of the initiation of OPA infusion (defined as Time 0). Exclusion 
criteria included a history of chronic liver disease, signs of overt uncal herniation or uncontrolled 
intracranial hypertension, significant gastrointestinal bleeding, hemodynamic instability defined 
by a mean arterial pressure of <65mmHg after volume resuscitation, QTc interval on baseline 
ECG of >500msec, or a history of heart failure, pulmonary hypertension, or concomitant 
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t   7medications known to interfere with renal excretion of PAGN (haloperidol, valproic acid, and 
others). Patients with ALI/ALF from pregnancy (acute fatty liver of pregnancy and the 
hemolysis-elevated liver chemistry-low platelet syndrome), acute Wilson Disease, malignancy 
and shock/ischemia were also excluded from participation. Lactulose and/or rifaximin were not 
permitted during the study period. Entry criteria were broadened during the study as early safety 
and tolerability assessments found no safety signals. Initially, enrollment was limited to patients 
with acetaminophen (APAP)-induced ALI/ALF because these patients are most likely to develop 
cerebral edema. Other etiologies were later admitted to the study as long as subjects met the 
baseline ammonia criterion of ≥60µM.  
 Data on safety and tolerability were collected from all 47 patients. In order to assess the 
efficacy of ammonia-lowering, patients were considered evaluable if they received at least 72h 
of OPA infusion, as defined a priori. Eleven patients failed to meet the 72h infusion criterion 
and were thus excluded from the ammonia assessment, but were included in pharmacokinetic 
(PK) assessment. Three of the 47 patients had no plasma samples available for determination of 
PK because they were removed from the study shortly after enrollment (one patient died, one 
was transplanted, and one withdrew consent/signed out against medical advice). 
 Study drug infusion scheme. OPA infusions were first administered to patients with 
relatively normal renal function (defined as a baseline serum creatinine ≤1.5mg/dl), and later, 
after clearance by a Safety Review Committee (SRC), to patients with impaired renal function 
(defined as serum creatinine >1.5mg/dl). For safety, OPA infusion doses were administered 
incrementally, starting at 3.3g/24h as a constant intravenous infusion. Preliminary studies 
showed that OPA and N-acetylcysteine (NAC) were compatible for infusion through the same 
intravenous line, and were well-tolerated through peripheral or central venous infusion. Three 
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t   8evaluable patients were enrolled at each dose level before beginning enrollment in the next dose 
level.  
 The dose escalation scheme is depicted in Figure 1. The beginning of OPA infusion was 
defined as Time 0. The first patient cohort received OPA 3.3g/24h for up to 120h. After safety 
and tolerability were assessed by the SRC, the second group received 3.3g/24h for 12h, then 
increased to 6.7g/24h for the remainder of the infusion if there were no safety signals as 
assessed by the site clinical investigator. The third cohort received the initial 3.3g/24h, the 
6.7g/24h dose for the subsequent 12h, and then 10g/24h for the remainder of the infusion, again, 
assuming there were no safety signals. Finally, since OPA infusions including the 10g/24h dose 
were deemed safe and well-tolerated by the SRC, a final cohort received a constant infusion of 
20g/24h for up to 120h. Some subjects received fewer than 120h infusion because the patient 
expired, was transplanted, withdrew consent, or improved and was discharged.  
 Clinical Evaluation. A complete physical exam, laboratory studies including ammonia, 
plasma and urine sampling for PK studies, and a safety assessment including ECG for QTc 
interval was performed during OPA infusion every 12h for the first 3 days and every 24h 
thereafter. Clinical evaluations included neurological assessment including recording of the 
hepatic encephalopathy grade according to West Haven Criteria, plasma ammonia, creatinine 
and other standard laboratory tests, and urinalysis. All evaluations and samples were also 
collected at completion of the OPA infusion, and 24 h following the completion of the infusion.  
 Laboratory Methods. PK studies were performed on plasma from blood samples drawn 
into EDTA-containing Vacutainers. Plasma samples for ammonia were collected in heparinized 
Vacutainer tubes and transported to the laboratory on ice. Samples were run for ammonia 
according to local protocol. Plasma PA/PAGN/ORN levels were determined using an ultra-
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t   9performance liquid chromatography (UPLC) method with tandem mass spectrometric 
detection.  The concentration range for all analytes was 5 to 1000µg/ml. Urine PAGN levels 
were determined using a UPLC method with tandem mass spectrometric detection.  The 
concentration range was 300 to 200,000µg/ml. 
 Data Collection and Management. The entire study duration for each patient was 
approximately 32 days; screening assessment, baseline, up to 5 days of treatment, follow up 
assessment 24h after completion of the last infusion, and a post-treatment visit approximately 30 
days after treatment day 1 unless terminated early from the trial.  
 Average plasma concentrations of ORN, PA, and PAGN during the infusions were 
obtained from the area under the curve (AUC) vs. time from 2-3 days until the end of the 
infusions, divided by the time period of infusion. Estimates of PAGN renal clearance were 
calculated by dividing the average daily excretion rate of PAGN by the average PAGN plasma 
concentration during the same period for each subject. To evaluate drug effects on blood 
ammonia concentrations, values for the percent decrease from Time 0 were calculated for each 
sampling time. The average percent decrease in ammonia concentration from 0-72h and from 0-
120h were then determined from the AUC for the percent decrease vs. time, divided by the 
infusion time of OPA.   
 Data on clinical outcomes were also collected during the study period. All data were 
collected and reviewed on a secure central server at the Medical University of South Carolina’s 
Data Coordination Unit, which serves as the data coordinating center for the ALF Study Group. 
Data were assessed through statistical and data management checks to ensure quality and 
verification.  
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t   10 Statistical Analysis. All statistical analyses were performed using SAS version 9.4 (SAS 
Institute, Cary, NC). Missing values were not replaced or estimated. Descriptive statistics 
characterized the demographics and other clinical variables. Categorical variables were 
compared using the Chi-square test, or Fisher’s exact test (when expected cell counts were <5). 
Medians were reported with interquartile ranges (IQR) and compared using the Wilcoxon rank 
sum test. Plasma concentration results were compared by ANOVA methods of log-transformed 
or rank values. The relationship between baseline creatinine and PK variables were examined 
with descriptive statistics.   
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t   11Results. 
Study population characteristics.  
 Forty-seven patients with ALI/ALF were enrolled into the study, 36 of whom were pre-
defined as evaluable (OPA infusion ≥72h) for measurement of ammonia-lowering efficacy 
(Table 1). The normal renal function cohort (serum creatinine at screening of ≤1.5mg/dl 
[N=30]) differed significantly from the impaired renal function cohort (creatinine >1.5mg/dl 
[N=17]) by percent female gender (80 vs. 41%, respectively), the proportion with 
acetaminophen (APAP) overdose as the etiology (83 vs. 41%), and by definition, median serum 
creatinine (0.7 vs. 2.5mg/dl), and percent on continuous renal replacement therapy (CRRT; 3.3 
vs. 59%, respectively).  
Plasma concentrations of study drug components and product at steady-state.  
 PK assessments included data from 44 of the 47 enrollments. Some of the 8 patients who 
received the lowest dose of OPA (3.3g/24h) had undetectably low plasma ORN, PA, and/or 
PAGN, and were thus omitted from the analyses in Figure 2, which depict plasma 
concentrations at steady-state according to maximal infusion rate of OPA. Plasma [ORN] at 
steady-state (Figure 2A) was neither related to the infusion rate of OPA nor affected by renal 
impairment. There was no relationship of plasma [ORN] to serum creatinine in patients who 
received the 6.7, 10, or 20g/24h infusion rate of OPA (P=0.76, 0.52, and 0.79, respectively [data 
not shown]). In contrast, mean plasma [PA] (Figure 2B) increased with the infusion rate of 
OPA, although was not significantly different in patients with normal and impaired renal 
function. There was no relationship between [PA] and creatinine concentrations in patients who 
received the 6.7, 10, and 20g/24h infusion rate (P=0.10, 0.38, and 0.71, respectively [data not 
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t   12shown]). Plasma [PAGN] increased not only with increasing OPA infusion rate but also in 
patients with renal impairment, compared to those with normal renal function (Figure 2C).  
Excretion of PAGN. 
 Figure 3 depicts the relationship of plasma [PAGN] and urinary PAGN excretion to 
renal function at baseline. As shown in Figure 3A, plasma [PAGN] increased as a function of 
baseline creatinine for the 6.7g/24h infusion rate (P=0.015), the 10g/24h rate (P=0.003), and the 
20g/24h rate (P<0.001). Moreover, renal PAGN clearance was linearly related to creatinine 
clearance with a slope of 1.18 (r=0.831; P<0.0001 [Figure 3B]). Renal clearance of PAGN was 
inversely related to plasma [PAGN] (Figure 3C), consistent with renal tubular secretion. The 
inverse relationship was stronger in patients with normal renal function (P<0.001) than with 
impaired renal function (P=0.002).  
 Eleven patients were treated with CRRT during OPA infusion. Samples of dialysate 
were also analyzed for PAGN. PAGN concentrations in dialysate were below the limit of 
detection in all samples. 
Effects of OPA on serum ammonia concentrations. 
 The current Phase 2a study was not designed to assess the efficacy of OPA in ammonia-
lowering nor improvement in grade of HE. Nevertheless, detailed information on ammonia 
concentrations and HE grade was collected during the study period and follow-up. Ammonia 
concentrations varied greatly between patients as well as within patients over time. In 5 study 
patients, all of whom died, ammonia inexorably increased during OPA infusion. Three of these 5 
patients received the 3.3g/24h OPA dose, and died of cerebral edema (N=1) and multi-organ 
system failure (MOSF) (N=2). The others (N=1 each) received 10g/24h and 20g/24h, and died of 
MOSF and septic shock, respectively. Although 2 of the 5 patients received OPA for ≥72h and 
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t   13were considered evaluable in the ammonia-lowering efficacy study, they were hemodynamically 
unstable and pre-terminal. Thus, the exploratory analysis of OPA on ammonia-lowering was 
based upon 34 patients, the 36 who received study drug for ≥72h excluding the 2 evaluable but 
pre-terminal patients with hemodynamic collapse, a condition which could not support effective 
ammonia-lowering by OPA. 
 The distribution of hepatic encephalopathy grades (by West Haven criteria(16)) and 
respective serum ammonia for each grade at Time 0 is shown in Figure 4. Of the entire 47 
patient cohort, 16 had no HE (ALI), while grade 1,2,3, and 4 HE was recorded in 8,8,4, and 11 
patients, respectively. The patients with HE grades 0-3 all had elevated blood ammonia levels 
with medians between 84 and 93µM, whereas the patients with grade 4 coma had significantly 
higher median ammonia than lower grades (137µM). Figure 5 depicts the average percent 
lowering of plasma ammonia based on AUC over two time periods, 0-72h (N=34 patients) and 0-
120h (N=29 patients). For patients with data available between 0-72h, the percent decrease in 
ammonia AUC concentrations in patients receiving 20g/24h was larger than in patients who 
received 3.3 or 6.7g/24h (P=0.048 and 0.030, respectively). For patients with data available 
between 0-120h, the percent decrease in ammonia AUC concentrations in those receiving 
20g/24h was significantly higher than those who received 3.3 or 6.7g/24h (P=0.046 and 0.022, 
respectively). We performed a 2-factor analysis examining a possible confounding effect of 
CRRT on ammonia-lowering by OPA. For the patients with 0-72h and 0-120h ammonia AUC 
data, RRT had no discernable effect on the decrease in ammonia AUC concentrations (P=0.346 
and 0.226, respectively; data not shown). Since most subjects enrolled in the study had no or 
low-grade (grade 1-2) HE at baseline (N=32), it was not possible to assess the effects of OPA on 
HE grade. 
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t   14Safety and tolerability of OPA in patients with ALI/ALF. 
 Adverse events (AEs) and their relatedness to the study drug are depicted in Table 2 for 
all 47 patients. All reported AEs classified by MedDRA Term are depicted in Supplemental 
Table 1 according to OPA infusion dose. AEs were expected in this trial because of the severity 
and global systemic effects of liver failure in patients with the ALF syndrome. Generally, OPA 
was safe and well-tolerated. Of a total of 107 AEs, 96 (90%) were deemed not related, or 
unlikely to be related, to the study drug by the site clinical investigator. Similarly, 92 (86%) were 
deemed non-life-threatening. All of the 26 severe, life-threatening, or fatal AEs were deemed not 
related, or unlikely to be related, to the study drug. AEs considered possibly related to the study 
drug by the site clinical investigators included abdominal pain, hypotension, nausea, pyrexia, 
thrombocytopenia, and vomiting. Six of these cases were deemed mild and two moderate, in 
severity. AEs considered probably related to the study drug included nausea, vomiting, and 
headache, two of which were mild, and one moderate, in severity. 
 The toxicity of OPA has been ascribed to plasma [PA], levels of which are associated 
with neurologic AEs when ≥500µg/ml(17, 18). Neurologic AEs ascribed to PA have included 
nausea, vomiting, headache, dizziness, lethargy, somnolence, confusion, and dysgeusia. Since 
the definition of the ALF syndrome includes altered sensorium and mentation, lethargy, 
somnolence and confusion were not specifically captured as AEs. There were 7 patients who 
experienced 8 neurologic AEs (nausea 1, headache 4 and vomiting 3). One patient had two 
reported AEs of vomiting. The median plasma [PA] in 6 of 7 patients with neurologic AEs ([PA] 
was not available in 1 patient) was 16.0 (range 5.0-168.0) µg/ml, compared to 43.7 (range 2.5-
490) µg/ml in patients without neurologic AEs (Wilcoxon P-value of 0.388).   
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t   15 Since biotransformation of PA to PAGN largely occurs in the liver, a plasma PA/PAGN 
ratio >2.5, reflecting hepatic dysfunction, has been suggested to predict high plasma [PA], and an 
increased likelihood of neurologic AEs in patients with cirrhosis(8). However, despite plasma 
PA/PAGN ratios frequently >2.5 in patients with ALI/ALF, the highest plasma AUC [PA] in any 
patient regardless of OPA dose or renal dysfunction was 326µg/ml (Supplemental Figure 3), 
well below the reported neurotoxic threshold. 
 ECG’s from 16 patients were electronically flagged by the ECG software as having QTc 
interval >500msec during study drug infusion. In all but 3 cases, the flagged QTc was found to be 
inaccurate when reviewed manually by a cardiologist. In these 3 cases, a more plausible 
alternative etiology was identified, including severe electrolyte derangement and pericarditis.  
Discussion. 
 The incidence of cerebral edema in patients with ALF appears to have decreased in recent 
years due to improvements in general intensive care and preventative measures(19, 20). Once 
established, however, cerebral edema remains one of the most highly mortal systemic 
complications of ALF(2). Non-specific medical therapies such as hypertonic saline and mannitol 
infusions merely provide temporary relief of cerebral edema because they treat the osmotic 
gradient driving water into astrocytes rather than treating the primary stimulus of the osmotic 
gradient, hyperammonemia.  
 In the present study of patients with ALI/ALF, PK data support the two mechanisms of 
action proposed for the ammonia-scavenging activity of OPA: provision of a substrate for 
glutamate production (ORN) and an agent to prevent the deamidation of glutamine and promote 
its renal excretion (PA). Plasma concentrations of ORN were not proportional to the dose of 
OPA, probably reflecting its rapid conversion to glutamate, suggesting that this step is not rate-
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t   16determining. The renal clearance of PAGN was strongly correlated with creatinine clearance yet 
inversely proportional to plasma [PAGN], suggesting that the rate-limiting step in ammonia 
elimination may be renal tubular secretion of PAGN. Although the primary site of synthesis of 
PAGN from PA and GLN is the liver(21), we found no relationship between [PAGN] or the 
PA/PAGN ratio and the severity of primary liver injury estimated by the INR (data not shown). 
This observation suggests that OPA should be effective as an ammonia scavenger regardless of 
the severity of liver injury in patients with ALF, and is consistent with previous studies reporting 
similar PAGN renal excretion in healthy volunteers and patients with cirrhosis and normal renal 
function regardless of Child-Pugh class(22). However, since the biotransformation of PA to 
PAGN appears to become saturated at higher doses of OPA, the efficiency of ammonia lowering 
may be compromised by more severe liver failure. 
 The bility of CRRT to eliminate PAGN in patients with renal failure remains unproven 
from this study, since [PAGN] in all samples of dialysate was below the limit of detection. 
Although a previous report suggests that PAGN is dialyzable in renal failure patients(23), the 
volume of dialysate collected in the present study was inadequate to attempt re-quantitation on a 
concentrated sample. However, PK data from one study participant indirectly suggests that 
CRRT can clear PAGN. The patient, a 33 year-old male with adult Reye’s Syndrome and 
oliguric renal failure, had the highest blood ammonia of the entire cohort (733µM on screening 
and 714µM at Time 0), and received the highest dose of OPA (20g/24h) promptly after 
admission (Supplemental Figure 4). At 24h of OPA infusion, CRRT was started, and serum 
ammonia concentrations decreased progressively to 59 and 30µM at 72 and 96h of infusion, 
respectively. Although PAGN was not detected in the patient’s dialysate, plasma [PAGN] at 
steady-state reached only 111µg/ml, a level exceeded by 7 other patients in the cohort, 4 of 
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t   17whom were not receiving CRRT. These observations suggest that CRRT may clear PAGN 
because plasma PAGN did not rise to very high concentrations despite profound 
hyperammonemia, and the patient never developed HE or cerebral edema. 
 A threshold plasma [PA] to effect ammonia elimination has not been systematically 
defined. However, based upon a study in patients with cirrhosis who received OPA doses of 
10g/24h, the maximal plasma [PA] of 25µg/ml was invoked as the reason for a lack of effective 
ammonia-lowering(14), compared to other studies exploring the administration of glycerol 
phenylbutyrate ([PA] 84-292µg/ml) and sodium phenylacetate ([PA] >120µg/ml)(24), which 
were highly effective. We informally chose a plasma [PA] of ≥75µg/ml a priori as a target level 
in the present study based upon these observations. Thus, many of our patients who received 
lower doses of OPA did not reach target plasma [PA]. In fact, only patients who received the 
20g/24h dose reliably reached plasma [PA] of 75µg/ml; none of those who received 3.3g/24h 
met target, whereas only one patient who received 20g/24h failed to reach target. Although 
previous studies of PA as a chemotherapeutic agent reported a neurotoxic threshold of PA of 
>500µg/ml(17, 18), this level was not approached in any patient with ALI/ALF receiving the 
20g/24h infusion regardless of renal failure or PA/PAGN ratio (Supplemental Figure 3). 
Therefore, these data suggest that a dose of 20g/24h may be optimal for patients with ALI/ALF.  
 The current study indicates that OPA is both safe and well-tolerated in patients with 
ALI/ALF. Only a minority of AEs were deemed possibly related to study drug, and all were 
non-life-threatening. Those AEs probably related to study drug included nausea, vomiting, and 
headache, all of which were graded non-serious by the site clinical investigator, and easily could 
be ascribed to the illness rather than the treatment. These AEs have been described in normal 
healthy volunteers treated with glycerol phenylbutyrate (a precursor of PA) as a function of 
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t   18increasing [PA], but resolved with continued dosing(8). However, we caution that most of the 
patients in the current study had altered mentation and may have under-reported these potential 
neurologic AEs. In addition, AEs ascribed to [PA] in previous studies also included confusion, 
lethargy, and somnolence(18), which would have been impossible to accurately distinguish from 
symptoms of severe liver injury in our patient population.  
 Although the current phase 2a study was not designed to assess the efficacy of OPA to 
lower ammonia in patients with ALI/ALF, the data suggest that OPA may be effective as an 
ammonia scavenger. Indeed, there was evidence of a dose-dependent decrease in average 
ammonia AUC concentrations between 0-72h and 0-120h of OPA infusion in patients who 
received 20g/24h compared to 3.3 or 6.7g/24h. CRRT had no discernable effect on ammonia-
lowering by OPA, although numbers of patients who received CRRT were small. The escalating 
dose scheme, designed for safety, may explain the delayed effect in ammonia-lowering; the 
insufficient dose of OPA in patients who received <20g/24h also played a role. These 
observations require confirmation with further studies of appropriate design. The effect of OPA 
on clinical outcome, improvement of HE or prevention or treatment of cerebral edema, could not 
be assessed by the present study, and also require further study. 
 The ammonia-lowering data also suggest that OPA may be futile in a subset of patients 
who are in the process of dying. Five patients were identified with steady increases in blood 
ammonia despite OPA infusion, 3 of whom died of multi-organ system failure, 1 of cerebral 
edema, and 1 of sepsis. Such patients would not be likely to respond to OPA, since intact 
circulation of OPA, its constituents, and PAGN requires proper delivery to the tissues illustrated 
in Supplemental Figure 1.  
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t   19 In summary, the current study suggests that OPA is safe and well-tolerated in patients 
with ALI/ALF, and supports the concept of OPA as a possible ammonia-scavenging agent by the 
mechanisms previously proposed(9). Although further studies are required to determine the 
efficacy of OPA, the preliminary data presented suggest that 20g/24h lowers serum ammonia in 
patients with ALI/ALF. 
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t   22Figure Legends. 
Figure 1. Ornithine phenylacetate (OPA) dose escalation scheme.  
*Number of patients enrolled into each infusion cohort (total N and [number of patients 
evaluable for the ammonia efficacy assessment who received ≥72h of OPA infusion]). 
 
Figure 2. Plasma concentrations of ornithine (A), phenylacetate (B), and 
phenylacetylglutamine (C) according to maximal infusion rate of ornithine phenylacetate in 
normal and renal-impaired subgroups.  
Data are shown for patients with “normal” and “impaired renal function” as defined in Methods.  
(ORN, ornithine; PA, phenylacetate; PAGN, phenylacetylglutamine). 
 
Figure 3. Concentration of phenylacetylglutamine (PAGN) in plasma and urine according 
to renal function.  
(A). Plasma PAGN concentration vs. baseline serum creatinine according to maximum infusion 
rate of OPA. (B). PAGN renal clearance vs. creatinine clearance. (C). Relationship of urinary 
PAGN clearance to plasma PAGN concentration. Data are shown for patients with “normal” and 
“impaired renal function” as defined in Methods.  
(ORN, ornithine; PA, phenylacetate; PAGN, phenylacetylglutamine). 
 
Figure 4. Plasma ammonia concentrations in the 47-patient study group by hepatic 
encephalopathy grade at Time 0. The number of patients in each group according to hepatic 
encephalopathy grade (West Haven Scale) for grade 0 (ALI) and grades 1-4 (ALF) are: 16, 
8,8,4,11, respectively.  
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t   23Figure 5. Decrease in serum ammonia with time of OPA infusion.  
Data are expressed as a percent change in average serum ammonia concentrations from time 0-
72h or 0-120h according to the maximal dose of OPA infusion (mean ± SEM).  
*For the AUC 0-72h, 20g/24h vs. 3.3g/24h P=0.048, and 20g/24h vs. 6.7g/24h P=0.030.  
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ALI (%) 46.7 35.3 0.391 
HE Grade 0/1, 2/3, 4 (%) 56.6, 26.7, 16.7 41.2, 23.5, 35.3 0.340 
OPA ≥72h (%) 76.7 76.4 0.988 
Age (Y) 35.0 (28.0-47.0) 38.0 (30.0-53.0) 0.319 
Female Gender (%) 80.0 41.2 0.007 
APAP (%) 83.3 41.2 0.003 
ALT (IU/L) 4305 (1562-7190) 3695 (892-6025) 0.405 
INR     3.1  (2.5-3.3) 3.3 (2.2-3.7) 0.391 
Bilirubin (mg/dL) 4.0 (2.8-8.0) 7.5 (3.4-17.6) 0.095 
Ammonia (µM) 89.0 (70.0-125.0) 103.0 (73.0-137.0) 0.775 
Creatinine (mg/dl)     0.7 (0.5-0.9) 2.5 (2.0-3.80 <0.0001 
Renal Replacement Therapy (%)     3.3 58.8 <0.0001 
 
Table 1. Baseline clinical characteristics of the entire study population according to renal 
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Not Related Unlikely Possibly* Probably** 
N % N % N % N % N % 
Total 61 100.0 % 35 100.0 % 8 100.0 % 3 100.0 % 107 100.0 % 
Mild 34 55.7 % 16 45.7 % 6 75.0 % 2 66.6 % 58 54.2 % 
Moderate 9 14.7 % 11 31.4 % 2 25.0 % 1 33.3 % 23 21.4 % 
Severe 5 8.1 % 6 17.1 % 0 0.0 % 0 0.0 % 11 10.2 % 
Life Threatening/ 
Disabling 
2 3.2 % 2 5.7 % 0 0.0 % 0 0.0 % 4 3.7 % 
Fatal 11 18.0 % 0 0.0 % 0 0.0 % 0 0.0 % 11 10.2 % 
 
 
Table 2. Adverse events and relatedness to study drug. 
 
*Events possibly related: abdominal pain, QTc prolongation >500msec on ECG, 
hypotension, nausea, pyrexia, thrombocytopenia (1 episode each), and vomiting (2 
episodes). 
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Figure 1  
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Figure 2  
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Figure 3  
 
338x451mm (96 x 96 DPI)  
Page 29 of 38
Hepatology
Hepatology









t   
 
 
Figure 4  
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Figure 5  
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OPA Dose (g/24h) 
3.3 6.7 10 20 
N % N % N % N % 
1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % Abdominal distension 
Abdominal pain 0 0.0 % 0 0.0 % 0 0.0 % 2 6.8 % 
Acute hepatic failure 1 2.6 % 1 6.2 % 2 8.3 % 0 0.0 % 
Alcohol poisoning 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Alcohol withdrawal syndrome 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Anemia 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Bradycardia 2 5.2 % 0 0.0 % 0 0.0 % 0 0.0 % 
Brain edema 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Cerebellar infarction 0 0.0 % 1 6.2 % 0 0.0 % 0 0.0 % 
Circulatory collapse 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Clostridial infection 0 0.0 % 1 6.2 % 0 0.0 % 0 0.0 % 
Compartment syndrome 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Confusional state 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Constipation 0 0.0 % 0 0.0 % 3 12.5 % 0 0.0 % 
Cough 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Deep vein thrombosis 2 5.2 % 0 0.0 % 0 0.0 % 0 0.0 % 
Dyspnea 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Edema 0 0.0 % 2 12.5 % 0 0.0 % 0 0.0 % 
Edema, peripheral 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Electrocardiogram QT interval 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Electrocardiogram QT prolonged 1 2.6 % 0 0.0 % 0 0.0 % 1 3.4 % 
Electrocardiogram ST segment elevation 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 



















OPA Dose (g/24h) 
3.3 6.7 10 20 
N % N % N % N % 
Headache 1 2.6 % 3 18.7 % 0 0.0 % 0 0.0 % 
Hepatic encephalopathy 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Hypertension 0 0.0 % 1 6.2 % 0 0.0 % 1 3.4 % 
Hypokalemia 0 0.0 % 1 6.2 % 1 4.1 % 2 6.8 % 
Hypomagnesemia 1 2.6 % 0 0.0 % 0 0.0 % 1 3.4 % 
Hypophosphatemia 0 0.0 % 0 0.0 % 1 4.1 % 2 6.8 % 
Hypotension 0 0.0 % 0 0.0 % 0 0.0 % 3 10.3 % 
Infusion site pain 0 0.0 % 1 6.2 % 0 0.0 % 0 0.0 % 
Leukocytosis 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Migraine 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Multi-organ failure 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Nausea 1 2.6 % 1 6.2 % 1 4.1 % 1 3.4 % 
Neurological decompensation 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Oliguria 7 18.4 % 0 0.0 % 0 0.0 % 0 0.0 % 
Oropharyngeal pain 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Pelvic pain 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Peritonitis 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Pneumonia 2 5.2 % 1 6.2 % 1 4.1 % 1 3.4 % 
Pyrexia 2 5.2 % 1 6.2 % 2 8.3 % 0 0.0 % 
Red man syndrome 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Renal failure acute 1 2.6 % 0 0.0 % 1 4.1 % 0 0.0 % 
Sepsis 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Septic shock 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 



















OPA Dose (g/24h) 
3.3 6.7 10 20 
N % N % N % N % 
Sinus congestion 0 0.0 % 1 6.2 % 0 0.0 % 1 3.4 % 
Subdural hematoma 0 0.0 % 1 6.2 % 0 0.0 % 0 0.0 % 
Tachycardia 7 18.4 % 0 0.0 % 0 0.0 % 0 0.0 % 
Tachypnea 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Thrombocytopenia 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Urinary tract infection 1 2.6 % 0 0.0 % 3 12.5 % 0 0.0 % 
Vision blurred 1 2.6 % 0 0.0 % 0 0.0 % 0 0.0 % 
Vomiting 0 0.0 % 0 0.0 % 1 4.1 % 2 6.8 % 
Wheezing 0 0.0 % 0 0.0 % 0 0.0 % 1 3.4 % 
Wound 0 0.0 % 0 0.0 % 1 4.1 % 0 0.0 % 
Supplemental Table 1. Complete reporting of adverse events by MedDRA Term according to infusion dose of OPA. 
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